UnitedHealth Group's stock surged over 8% to above $300 following a favorable Medicare Advantage reimbursement decision by CMS, turning a previous policy concern into a positive catalyst. This move has sparked strong buying interest, though technical analysis suggests the stock faces resistance between $300 and $400, a key zone where prior declines began. Investors are optimistic about the company's cost-cutting and AI-driven efficiency ahead of its April 21 earnings report, but concerns remain over projected membership losses in Medicare Advantage for 2026. The key question now is whether UnitedHealth can sustain gains above $300 to challenge higher resistance levels.
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
